Faricimab improves visual acuity, reduces central subfield thickness
October 04, 2022
3 minute watch
LimJI. Year 2 anti-VEGF/anti-Ang2 results for diabetic macular edema and neovascular AMD. Presented at the meeting of the American Academy of Ophthalmology; Sept. 30-Oct. 3, 2022; Chicago.
Disclosures: Lim is a consultant for Genentech and Regeneron.
CHICAGO – In this Healio video perspective of the AAO meeting, Jennifer I. Lim, MARYLAND, discusses Year 1 and Year 2 data for faricimab for the treatment of age-related macular degeneration and diabetic macular edema.
According to Lim, faricimab treatment resulted in improvements in visual acuity and reductions in central subfield thickness and demonstrated prolonged durability.